Question 1

What is Tango Therapeutics's P/S ratio?

Accepted Answer

Tango Therapeutics (TNGX) P/S ratio is 67.3× as of July 27, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Tango Therapeutics?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Tango Therapeutics specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Tango Therapeutics's P/S ratio high or low?

Accepted Answer

Tango Therapeutics's P/S ratio of 67.3× is above its own 5-year average of 21.3× and above the sector median of 3.4×. That places the current reading at the 97th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Tango Therapeutics's historical P/S ratio range?

Accepted Answer

In the available daily series, Tango Therapeutics (TNGX) P/S ratio has ranged from a low of 2.8× in 2025 to a high of 130.7× in 2020. The 5-year average is 21.3× and the 5-year median is 20.7×.

Question 7

What was Tango Therapeutics's P/S ratio in 2025?

Accepted Answer

Tango Therapeutics (TNGX) P/S ratio at the end of 2025 was 16.5×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Tango Therapeutics's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$1.03B	$62.4M	16.5×	+8.5×	Dec 31, 2025
2024	$336M	$42.1M	8.0×	-18.0×	Dec 31, 2024
2023	$948M	$36.5M	26.0×	+0.3×	Dec 31, 2023
2022	$638M	$24.9M	25.7×	-0.2×	Dec 31, 2022
2021	$958M	$37M	25.9×	-104.9×	Dec 31, 2021
2020	$1B	$7.66M	130.7×	—	Dec 31, 2020


AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Quest Diagnostics (DGX)	2.0×
Charles River (CRL)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
Solventum (SOLV)	1.4×
HCA Healthcare (HCA)	1.1×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
Molina Healthcare (MOH)	0.3×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Tango Therapeutics (TNGX) 2020-2026

P/S Ratio daily chart for Tango Therapeutics (TNGX)

Historical P/S Ratio for Tango Therapeutics (TNGX) from 2020 to 2025

About P/S Ratio at Tango Therapeutics (TNGX)

Tango Therapeutics P/S Ratio by Year

Tango Therapeutics P/S Ratio 2025: 16.5×

Tango Therapeutics P/S Ratio 2024: 8.0×

Tango Therapeutics P/S Ratio 2023: 26.0×

Tango Therapeutics P/S Ratio 2022: 25.7×

Tango Therapeutics P/S Ratio 2021: 25.9×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Tango Therapeutics (TNGX) Key Financials